It is designed to not only prevent the recurrence of cancer but also to significantly reduce the side effects associated with traditional cancer treatments by up to 50 percent.
The team developed a pro-oxidant tablet containing resveratrol, a natural compound, and copper (R+Cu), which produces oxygen radicals skilled at destroying the chromatin particles.
Researchers claim that the combination of resveratrol and copper has been shown to deactivate harmful cell-free chromatin particles (cfChPs), released by dying cancer cells.
The research team is currently awaiting approval from the Food Safety and Standards Authority of India (FSSAI), with hopes of the tablet hitting the market by mid-year.
“Human trials are expected to take approximately five years to complete,” shares Dr Rajendra Badve, a senior cancer surgeon and a key member of the research team.
Many oncologists preferred to reserve their judgments until a peer-reviewed publication of the research was available, especially since human trials have to be conducted.